Artiva Biotherapeutics, Inc. 8K

Artiva Biotherapeutics announced second quarter 2026 financial results, bolstered its cash position via a $300 million offering, reported positive AlloNK® clinical progress including FDA RMAT designation, and outlined plans to start a Phase 3 RA trial in the second half of 2026.

Artiva Biotherapeutics, Inc. reported its unaudited financial results for the quarter ended June 30, 2026, highlighted by a significant strengthening of its balance sheet to $349.4 million in cash, cash equivalents and investments following an approximately $300 million underwritten equity offering in May 2026, and provided business updates including positive AlloNK® clinical data in refractory rheumatoid arthritis and other B‑cell-driven autoimmune diseases presented at EULAR 2026, receipt of FDA Regenerative Medicine Advanced Therapy (RMAT) designation for AlloNK plus rituximab in refractory RA, plans to initiate a Phase 3 registrational randomized controlled trial in the second half of 2026, and the appointment of Diego Miralles, M.D., as president and head of research and development, while disclosing a quarterly net loss of $25.0 million driven primarily by increased research and development expenses.

Filing Facts

CIK

1817241

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-337986

Alert Tier

6